Novadaq Technologies Inc.

Novadaq Technologies Inc.

November 01, 2006 10:41 ET

Novadaq to Hold Third Quarter 2006 Conference Call and Webcast

TORONTO, ONTARIO--(Marketwire - Nov. 1, 2006) -

Attention Business Editors:

Novadaq® Technologies Inc. (TSX:NDQ), a developer of medical imaging systems
for the operating room, will host a conference call and live webcast on Monday,
November 6, 2006 at 4:30 p.m. E.T. to discuss the financial results for the third
quarter ended September 30, 2006.

To access the conference call by telephone, dial 416-644-3414 or
1-800-814-4862. Please connect approximately ten minutes prior to the
beginning of the call to ensure participation. The conference call will be
archived for replay until November 13, 2006 at midnight. To access the
archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the
reservation number 21208114 followed by the number sign.

A live audio webcast of the conference call will be available at Please connect at least ten minutes prior to the conference
call to ensure adequate time for any software download that may be required to
join the webcast. The webcast will be archived at the above website for 90

About Novadaq Technologies

Novadaq Technologies Inc. (TSX:NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular and ophthalmic diseases and conditions. Novadaq's
SPY Intra-operative Imaging System, commercially available worldwide, enables
cardiac surgeons to visually assess coronary vasculature and bypass graft
functionality during the course of open-heart surgery. Novadaq's ophthalmic
product, the OPTTX® System, is aimed at the diagnosis, evaluation and
treatment of wet Age-related Macular Degeneration (AMD) by using the same core
imaging technology that is used in the SPY System. Novadaq filed for CE Mark
approval for the OPTTX System at the end of Q2 2006 and expects a limited
launch in Europe by year end. Novadaq's product for urology, LUNA™ is
designed to enable surgeons to visualize nerve bundles during the course of
urological procedures such as radical prostatectomy in order to reduce
negative outcomes including impotency. For more information, please visit the
company's website at

Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Novadaq in its public securities filings; actual
events may differ materially from current expectations. Novadaq disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

For further information: visit our website at

Contact Information